Arrowhead Pharma (ARWR) Price Target Raised to $115 After Trial Data
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowH.C. Wainwright has raised the price target for Arrowhead Pharmaceuticals (ARWR) to $115 based on new trial data. This adjustment comes as trial results indicate promising developments that could positively impact the company's valuation. Typically, price target revisions from analysts can affect investor sentiment and trading patterns. For ordinary investors, this increase suggests a potentially favorable market outlook for Arrowhead Pharmaceuticals going forward.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
